Crossmark

Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia

Crossref DOI link: https://doi.org/10.1038/leu.2017.282

Published: 2018-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Waibel, M

Vervoort, S J

Kong, I Y

Heinzel, S

Ramsbottom, K M

Martin, B P

Hawkins, E D

Johnstone, R W
License Information

Text and Data Mining valid from 2017-09-15
More Information

Article History

First Online: 15 September 2017

Competing interests

: The Johnstone laboratory receives research funding from Novartis for studies involving panobinostat.